Georgene Ellen Hergenroeder, MD
Assistant Professor of Clinical Pediatrics (Pulmonary Medicine)
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
3500 Civic Center Blvd
Philadelphia, PA 19104
3500 Civic Center Blvd
Philadelphia, PA 19104
Education:
BA
University of Texas at Austin, 2013.
MD
Baylor College of Medicine, 2017.
Permanent linkBA
University of Texas at Austin, 2013.
MD
Baylor College of Medicine, 2017.
Selected Publications
Rosen BH, Psoter KJ, Sabadosa KA, Hergenroeder GE, Bendy LL, Luo NM, Zhang C, Ren CL, Brown CD: Using Real-World Research to Study the Impact of Chronic Daily Therapy Discontinuation in Cystic Fibrosis: The Home Reported Outcomes in Cystic Fibrosis 2 (HERO-2) Study Design. CHEST Pulmonary 2024 Notes: https://doi.org/10.1016/j.chpulm.2024.100080.G. Hergenroeder, JT, C. Goss, R. Jain, W. Morgan, G. Sawicki, M. Schechter, C. Ren. : Black and Hispanic people with cystic fibrosis (PwCF) and PwCF with high lung function are less likely to be prescribed elexacaftor-tezacaftor-ivacaftor despite having an eligible genotype. J Cystic Fibros 22: S205-206, October 2023 Notes: DOI:10.1016/S1569-1993(23)01328-0.
G. Hergenroeder, K. Psoter, C. Brown, K. Sabadosa, L. Bendy, B. Rosen, N. Luo, C. Zhang, C. Ren: Clinical features associated with changes in chronic daily therapies in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor: Results from the Home Reported Outcomes 2 Study Journal of Cystic Fibrosis 22: S325, October 2023 Notes: DOI: 10.1016/S1569-1993(23)01532-1.
Hergenroeder, G.E., Faino, A.V., Cogen, J.D., Genatossio, A., McNamara, S., Pascual, M., & Hernandez, R.E: Seroprevalence and clinical characteristics of SARSCoV‐2 infection in children with cystic fibrosis. Pediatric Pulmonology September 2023 Notes: https://doi.org/10.1002/ppul.26528.
Hergenroeder, G.E., Faino, A., Bridges, G., Bartlett, L.E., Cogen, J.D., Green, N., McNamara, S., Nichols, D.P., & Ramos, K.J. : The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis. Journal of Cystic Fibrosis August 2023 Notes: https://doi.org/10.1016/j.jcf.2023.08.002.
Anderson J, Mallory T, Romberg E, Riehle K, Kapur R, Crocker M, Crotty E, Hergenroeder G, Greenberg SLM: Mature mediastinal teratoma with tumor rupture into airway. Journal of Pediatric Surgery Case Reports 81(1): 102270, Jun 2022.
Cogen J, Hergenroeder G, Faino A, Genatossio A, McNamara S, Pascual M, Hernandez R, : Seroprevalence and Clinical Characteristics of SARS-CoV-2 Infection in Children and Adolescents with Cystic Fibrosis. Center for Clinical and Translational Research Science Day, Seattle Children's Hospital, Seattle, WA 2022 Notes: Poster.
Hergenroeder G, Faino A, Bridges G, Bartlett L, McNamara S, Strub B, Nichols D, Ramos K: The impact of elexacaftor/tezacaftor/ivacaftor (Trikafta) on serum markers of fat-soluble vitamin levels in people with cystic fibrosis. North American Cystic Fibrosis Conference Meeting, Philadelphia, PA 2022 Notes: Poster.
Hergenroeder GE, Cogen JD: Exasperation with the Lack of Pulmonary Exacerbation Treatment Standardization. Journal of Cystic Fibrosis 20(6): 901-903, Nov 2021.
Hergenroeder G, Cogen J, Genatossio A, Gorry S, McNamara S, Hernandez R: Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children and adolescents with cystic fibrosis. Seattle Children’s Hospital Fellow and Resident Research Day, Seattle, WA 2021 Notes: Poster.